At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 146 enrolled
Drug / intervention
SB656933 +2 moredrug
Likely dose
SB656933 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
In Brief
A Phase 2 clinical trial evaluating SB656933 and Placebo for Cystic Fibrosis. Completed, enrolled 146 participants across 33 sites in 5 countries.
Detailed Summary
The purpose of this study is to determine whether the safety, tolerability and pharmacodynamics of SB656933 in patients that have cystic fibrosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesCanada, France, Germany, Israel, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartSep 2009
Primary CompletionDec 2010
TodayJul 2026
First PostedMay 18, 2009
Enrollment StartSep 28, 2009
Primary CompletionDec 29, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.1 years ago
Interventions
SB656933drug
20 mg
SB656933drug
50mg
Placebodrug
placebo